ScreenerHero
ONCINOncoinvent ASA
OSL · NO · Healthcare · Biotechnology · oncoinvent.com
83.20NOK+0.97%Mkt Cap: 34.83M $P/E: —

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap34.83M $
Enterprise Value18.23M $
Revenue (TTM)2.62M $
Gross Profit2.62M $
Net Income (TTM)-14.50M $
Revenue/Share2.117 USD
Last Price83.20 NOK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees44
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0013711713
Valuation
P/E (Trailing)—
P/E (Forward)-3.07
PEG—
EV/EBITDA-1.30
EV/Revenue6.95
P/S12.80
P/B2.45
EPS (TTM)-125.00
EPS (Forward)-26.14
52W Range
40.1080% of range94.00
52W High94.00 NOK
52W Low40.10 NOK
Profitability
Gross Margin100.00%
Oper. Margin-659.95%
EBITDA Margin0.00%
Profit Margin-673.13%
ROE-105.98%
ROA-75.66%
Growth
Revenue Growth100.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.14M $
CapEx (TTM)11.12K $
FCF Margin-303.52%
FCF Yield-22.86%
Net Debt-16.27M $
Net Debt/EBITDA1.16
Balance Sheet
Debt/Equity0.02
Current Ratio3.23
Quick Ratio3.20
Book Value/Sh32.67 NOK
Cash/Share39.66 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateJan 19, 2026
Analyst Consensus
Rating—
Target (Mean)59.50 NOK
Upside (mean)-28.5%
Target Range49.00 NOK – 70.00 NOK
NOK49.00-28.5% to meanNOK70.00
# Analysts2
Ownership
Shares Out.4.48M
Float3.00M
Insiders23.07%
Institutions38.70%
Technical
SMA 5068.56 (+21.3%)
SMA 20053.22 (+56.3%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)8.63K
Avg Vol (10d)6.78K
Technical Indicators
RSI (14)54.3
MACD4.3726
MACD Signal5.2339
MACD Hist.-0.8613
BB Upper90.84 NOK
BB Middle83.78 NOK
BB Lower76.72 NOK
BB Width16.85%
ATR (14)5.741 NOK
Vol Ratio (20d)1.33x